WEHI-231 Syngeneic Model Overview
The WEHI-231 syngeneic model is a murine B-cell lymphoma system derived from BALB/c mice and serves as a classical model for studying B-cell development, immune tolerance, and lymphoma immunobiology. Originating from a spontaneous neoplasm of immature B cells, WEHI-231 represents an early-stage B-cell lymphoma characterized by high proliferative potential and defined immunoregulatory properties. This model is widely used to investigate signaling pathways involved in B-cell receptor (BCR) activation, apoptosis, and tolerance mechanisms, as well as for evaluating immunotherapy and targeted agents in preclinical hematologic research.
When implanted subcutaneously or intravenously, WEHI-231 cells form moderately aggressive tumors that grow reproducibly in immunocompetent BALB/c mice. The model’s consistent growth kinetics and well-characterized immunophenotype make it a valuable system for testing B-cell–directed immunotherapies, checkpoint inhibitors, and cytokine-modulating compounds.
Request a Custom Quote for WEHI-231 Syngeneic ModelBiological and Molecular Characteristics
The WEHI-231 cell line was derived from a spontaneous B-cell lymphoma in BALB/c mice and exhibits characteristics of immature, surface immunoglobulin–positive (sIg⁺) B cells. The cells express CD19, CD20, and MHC class II, while maintaining functional BCR signaling and sensitivity to apoptosis following BCR engagement. Because of this, WEHI-231 has been a central model for studying negative selection and self-tolerance in B-cell maturation.
Molecularly, WEHI-231 tumors display activation of NF-κB, PI3K-AKT, and MAPK signaling pathways, contributing to proliferation and survival. The tumor microenvironment features macrophage and T-cell infiltration, along with expression of PD-L1 and secretion of immunomodulatory cytokines such as IL-6 and TGF-beta. These features enable exploration of immune evasion, tumor–host interactions, and therapeutic modulation of B-cell signaling pathways.
| Parameter | Description |
|---|---|
| Host strain | BALB/c (female, 6–8 weeks) |
| Tumor origin | Spontaneous immature B-cell lymphoma (mouse) |
| Histological type | B-cell lymphoma |
| Inoculation route | Subcutaneous or intravenous |
| Tumor take rate | >90% |
| Doubling time | Approximately 3–4 days in vivo |
| Metastatic potential | Low to moderate; systemic spread via IV route |
| Immunophenotype | CD19⁺, CD20⁺, MHC-II⁺, sIg⁺, PD-L1⁺ |
| Common applications | B-cell biology, immunotherapy, checkpoint blockade, tolerance and apoptosis studies |
In Vivo Model Development and Tumorigenicity
WEHI-231 tumors can be established through subcutaneous or intravenous injection of viable cells into immunocompetent BALB/c mice. Subcutaneous implantation produces solid tumors with measurable growth for efficacy assessment, while intravenous inoculation results in disseminated disease suitable for systemic lymphoma studies. Tumors typically develop within 7–10 days and progress with moderate aggressiveness.
This model’s stable tumor kinetics and partially immunogenic profile make it ideal for studying immune modulation and targeted therapy. Because WEHI-231 cells respond to both immune-mediated and small-molecule interventions, the model is frequently used in preclinical testing of B-cell signaling inhibitors, cytokine therapies, and immunomodulatory drug combinations. Its ability to reflect early-stage B-cell transformation also supports its use in mechanistic research on lymphoma initiation and progression.
Request a Custom Quote for WEHI-231 Syngeneic ModelHistopathology and Immunohistochemical Profile
Histopathological analysis of WEHI-231 tumors reveals densely packed lymphoid cells with round nuclei, scant cytoplasm, and frequent mitotic figures. The tumors exhibit diffuse growth with minimal fibrosis and moderate vascularization. In systemic models, infiltration of the spleen, liver, and bone marrow is observed, reflecting disseminated B-cell lymphoma behavior.
Immunohistochemical staining confirms strong expression of CD19, CD20, and surface immunoglobulin, consistent with B-cell lineage. Ki-67 labeling demonstrates high proliferative activity, while PD-L1 expression is moderate and inducible under cytokine stimulation. CD3 and CD8 staining identify scattered T-cell infiltration at the tumor periphery, and CD11b and F4/80 staining highlight macrophage and myeloid cell presence within the stroma. These features collectively recreate the immunobiology of immature B-cell lymphoma and provide a relevant platform for evaluating immunomodulatory and targeted agents.
Preclinical Applications and Drug Response
The WEHI-231 syngeneic model is extensively used to study B-cell signaling, apoptosis, and tolerance, as well as to evaluate novel therapeutic strategies targeting B-cell malignancies. It has served as a benchmark model for exploring BCR-mediated apoptosis, the effects of checkpoint inhibition, and cytokine regulation within the lymphoma microenvironment. The model exhibits measurable responsiveness to immunotherapies such as PD-1 and CTLA-4 blockade, as well as to agents targeting NF-κB and PI3K pathways.
WEHI-231 has also been used to evaluate the effects of radiation, cytokine therapy, and combination regimens involving immune stimulants or small-molecule inhibitors. Its defined immunophenotype, reproducible tumor growth, and moderate immune responsiveness make it a highly versatile tool for translational research in B-cell lymphoma, immunotherapy development, and immune tolerance studies.
Request This Model
To request the WEHI-231 syngeneic model for your preclinical studies, please use the form below. A customized quote and additional model specifications will be provided upon inquiry.
Request a Custom Quote for WEHI-231 Syngeneic Model